- General
- September 8, 2020
- 3 minutes read
Zymergen Raises $300 Million
Joshua Hoffman, Chief Executive Officer, Zymergen. Photo credit: World Economic Forum / Sikarin Fon Thanachaiary, under Creative Commons license Zymergen,…
 |
| Joshua Hoffman, Chief Executive Officer, Zymergen.
Photo credit: World Economic Forum / Sikarin Fon Thanachaiary, under Creative Commons license
|
Zymergen, an Emeryville, California-based synthetic biology upstart, has raised $300 million in new funding from investors including Baillie Gifford, Baron Capital, SoftBank, True Ventures, and DCVC. With the new funding, Zymergen has now raised a total of nearly $900 million in funding since its inception. The valuation that came with the round isn’t disclosed.
Zymergen, a synthetic biology startup, is focused on creating materials from microbes. The seven-year-old company doesn’t seem to be fully mature yet, with a limited number of customers currently known. Zymergen seems to still be focused on research and development, an area where the new funding comes in handy. Before now, Zymergen is known to have raised north of $500 million in funding.
Zymergen launched its first commercially available product in April of this year. The product, named Hyaline, is a bio-manufactured film for electronic devices. The company says it plans to unveil other new products from now through next year.
